BR112013025275A2 - derivados de cefalosporina e suas composições farmacêuticas - Google Patents

derivados de cefalosporina e suas composições farmacêuticas

Info

Publication number
BR112013025275A2
BR112013025275A2 BR112013025275A BR112013025275A BR112013025275A2 BR 112013025275 A2 BR112013025275 A2 BR 112013025275A2 BR 112013025275 A BR112013025275 A BR 112013025275A BR 112013025275 A BR112013025275 A BR 112013025275A BR 112013025275 A2 BR112013025275 A2 BR 112013025275A2
Authority
BR
Brazil
Prior art keywords
cephalosporin derivatives
present
pharmaceutical compositions
prodrug
solvate
Prior art date
Application number
BR112013025275A
Other languages
English (en)
Inventor
Chul Soon Park
Dae Hyuck Kang
Hyang Sook Lee
Hye Jin Heo
Hyun Jin Kwon
Joung Yul Yun
Kyuman Oh
Sang Eun Chae
Sung Ho Woo
Tae Kyo Park
Yong Zu Kim
Young Jae Yang
Young Lag Cho
Original Assignee
Legochem Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Legochem Biosciences Inc filed Critical Legochem Biosciences Inc
Publication of BR112013025275A2 publication Critical patent/BR112013025275A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/60—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 3 and 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/02—Preparation
    • C07D501/04—Preparation from compounds already containing the ring or condensed ring systems, e.g. by dehydrogenation of the ring, by introduction, elimination or modification of substituents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C07D501/38—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof
    • C07D501/46—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof with the 7-amino radical acylated by carboxylic acids containing hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

resumo patente de invenção: "derivados de cefalosporina e suas composições farmacêuticas". a presente invenção refere-se a novos derivados de cefalosporinas, representados pela fórmula química 1. (1) em que, x, y, l, r1 e r2 são as mesmas como definidas, na descrição da invenção. a presente invenção também refere-se a composições de antibiótico farmacêuticas compreendendo um novo derivado de cefalosporina representado pela fórmula química 1, um pró-fármaco, um hidrato, um solvato, um isômero dos mesmos, ou um sal farmaceuticamente aceitável do mesmo, como um ingrediente eficaz. de acordo com a presente invenção, novos derivados de cefalosporinas, um pró-fármaco, um hidrato, um solvato, um isômero ou um sal farmaceuticamente aceitável do mesmo, como um ingrediente eficaz para o amplo espectro de antibiótico resistente, baixa toxicidade, particularmente em bactérias gram-negativas, que podem ser úteis com forte atividade antimicrobiana.
BR112013025275A 2011-03-30 2012-03-29 derivados de cefalosporina e suas composições farmacêuticas BR112013025275A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020110028603A KR101719556B1 (ko) 2011-03-30 2011-03-30 신규한 세파로스포린 유도체 및 이를 함유하는 의약 조성물
PCT/KR2012/002302 WO2012134184A2 (ko) 2011-03-30 2012-03-29 신규한 세파로스포린 유도체 및 이를 함유하는 의약 조성물

Publications (1)

Publication Number Publication Date
BR112013025275A2 true BR112013025275A2 (pt) 2016-12-13

Family

ID=46932135

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013025275A BR112013025275A2 (pt) 2011-03-30 2012-03-29 derivados de cefalosporina e suas composições farmacêuticas

Country Status (27)

Country Link
US (2) US8329684B2 (pt)
EP (1) EP2706062B1 (pt)
JP (1) JP6144669B2 (pt)
KR (1) KR101719556B1 (pt)
CN (1) CN103547583B (pt)
AU (1) AU2012237063B2 (pt)
BR (1) BR112013025275A2 (pt)
CA (1) CA2831421C (pt)
CL (1) CL2013002820A1 (pt)
CO (1) CO6821935A2 (pt)
CR (1) CR20130501A (pt)
CU (1) CU20130125A7 (pt)
DK (1) DK2706062T3 (pt)
DO (1) DOP2013000214A (pt)
EA (1) EA024709B1 (pt)
ES (1) ES2683351T3 (pt)
HR (1) HRP20181170T1 (pt)
HU (1) HUE039086T2 (pt)
IL (1) IL228408A (pt)
LT (1) LT2706062T (pt)
MX (1) MX359435B (pt)
PL (1) PL2706062T3 (pt)
PT (1) PT2706062T (pt)
SG (1) SG193998A1 (pt)
SI (1) SI2706062T1 (pt)
WO (1) WO2012134184A2 (pt)
ZA (1) ZA201308078B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2702257C (en) 2007-10-09 2016-07-12 Sopharmia, Inc. Broad spectrum beta-lactamase inhibitors
JP2017527604A (ja) 2014-09-17 2017-09-21 アイアンウッド ファーマシューティカルズ インコーポレイテッド ｓＧＣ刺激剤
US10059680B2 (en) * 2014-12-18 2018-08-28 Merck Sharp & Dohme Corp. Thiadiazolyl-oximinoacetic acid derivative compounds
US20160176897A1 (en) 2014-12-23 2016-06-23 Merck Sharp & Dohme Corp. 7-aminocephem derivative compounds
AU2016367284C1 (en) 2015-12-10 2018-09-20 Naeja-Rgm Pharmaceuticals Ulc Cephem compounds, their production and use
EP3526225A1 (en) * 2016-10-14 2019-08-21 Universidade do Porto Hydroxycinnamic derivatives, methods and uses thereof
KR20180093307A (ko) * 2017-02-13 2018-08-22 주식회사 레고켐 바이오사이언스 4, 5-디아미노 치환 피리미딘 유도체의 제조방법 및 이를 제조하기 위한 신규한 화합물
WO2019145784A2 (en) * 2018-01-26 2019-08-01 Legochem Biosciences, Inc. Combination therapies for multi-drug resistant pathogens
CN109762791B (zh) * 2018-11-19 2021-02-09 厦门联合安金生物工程有限公司 包含BPI-Fc嵌合基因的重组腺病毒及其用途
CN111471058A (zh) * 2019-01-23 2020-07-31 中国医学科学院药物研究所 用于制备头孢吡普类似物的方法
US20220332728A1 (en) 2019-09-06 2022-10-20 Nabriva Therapeutics GmbH Siderophore cephalosporin conjugates and uses thereof
CN111635377A (zh) * 2020-06-30 2020-09-08 南京红杉生物科技有限公司 噻二唑类化合物及其合成方法
KR20220152157A (ko) * 2021-05-07 2022-11-15 한국생명공학연구원 신규 사이드로포어 화합물 및 이를 이용한 금속 나노입자 복합체

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3006888A1 (de) * 1980-02-23 1981-09-10 Hoechst Ag, 6000 Frankfurt Cephalosporinderivate und verfahren zu ihrer herstellung
EP0303172A3 (de) * 1987-08-14 1991-05-15 F. Hoffmann-La Roche Ag Oxyimino-Cephalosporine
GB8817653D0 (en) * 1988-07-25 1988-09-01 Fujisawa Pharmaceutical Co New cephem compounds & processes for preparation thereof
GB9111406D0 (en) * 1991-05-28 1991-07-17 Fujisawa Pharmaceutical Co New cephem compounds and processes for preparation thereof
US5498777A (en) * 1994-07-20 1996-03-12 Merck & Co., Inc. 3-thioheteroaryl cephalosporin compounds, compositions and methods of use
TW200305422A (en) * 2002-03-18 2003-11-01 Shionogi & Co Broad spectrum cefem compounds
JP4555823B2 (ja) * 2003-07-11 2010-10-06 セラヴァンス， インコーポレーテッド 架橋されたグリコペプチド−セファロスポリン抗生物質
JPWO2005085258A1 (ja) * 2004-03-05 2007-12-13 塩野義製薬株式会社 ３−ピリジニウムメチルセフェム化合物
AU2005202802A1 (en) * 2004-06-28 2006-01-12 Astellas Pharma Inc. Cephem compounds
CN101230070A (zh) * 2006-12-30 2008-07-30 黄振华 新型抗感染头孢类化合物
RS55365B1 (sr) * 2008-10-31 2017-03-31 Shionogi & Co Cefalosporin sa kateholskom grupom

Also Published As

Publication number Publication date
SI2706062T1 (sl) 2018-11-30
JP6144669B2 (ja) 2017-06-07
CO6821935A2 (es) 2013-12-31
US20120264727A1 (en) 2012-10-18
MX359435B (es) 2018-09-28
CA2831421A1 (en) 2012-10-04
CR20130501A (es) 2014-05-13
EP2706062A2 (en) 2014-03-12
DK2706062T3 (en) 2018-08-06
EA201391325A1 (ru) 2014-04-30
ES2683351T3 (es) 2018-09-26
HUE039086T2 (hu) 2018-12-28
PT2706062T (pt) 2018-09-28
EA024709B1 (ru) 2016-10-31
US20130178455A1 (en) 2013-07-11
CL2013002820A1 (es) 2014-04-11
CN103547583B (zh) 2016-11-16
KR20120110625A (ko) 2012-10-10
KR101719556B1 (ko) 2017-03-24
CU20130125A7 (es) 2014-03-26
MX2013010961A (es) 2014-03-27
SG193998A1 (en) 2013-11-29
JP2014510750A (ja) 2014-05-01
WO2012134184A2 (ko) 2012-10-04
PL2706062T3 (pl) 2018-11-30
IL228408A0 (en) 2013-12-31
WO2012134184A3 (ko) 2013-03-07
HRP20181170T1 (hr) 2018-11-02
WO2012134184A8 (ko) 2013-10-24
US8329684B2 (en) 2012-12-11
CN103547583A (zh) 2014-01-29
ZA201308078B (en) 2019-01-30
DOP2013000214A (es) 2013-12-15
CA2831421C (en) 2019-06-04
EP2706062B1 (en) 2018-05-09
AU2012237063B2 (en) 2017-03-16
IL228408A (en) 2017-01-31
EP2706062A4 (en) 2015-01-21
AU2012237063A1 (en) 2013-10-17
LT2706062T (lt) 2018-10-25
US9630977B2 (en) 2017-04-25

Similar Documents

Publication Publication Date Title
BR112013025275A2 (pt) derivados de cefalosporina e suas composições farmacêuticas
BR112015022643A2 (pt) inibidores diidro-pirrolpiridinona
BRPI0607308A2 (pt) compostos, composições farmacêuticas e usos dos referidos compostos
BR112015022861A8 (pt) inibidores de bromodomínio
MX2020001453A (es) Compuestos de dihidroazol antiparasiticos y composiciones que comprenden los mismos.
BRPI0821855B8 (pt) composto, composição farmacêutica, e, uso de um composto ou sal farmaceuticamente aceitável do mesmo
BR112014017749A8 (pt) Composto alquinilbenzeno 3,5-dissubstituído e sal do mesmo
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
NZ596628A (en) Ketolide compounds having antimicrobial activity
BR112014013571A2 (pt) compostos herbicidas
CO6630184A2 (es) Formulaciones famacéuticas que comprenden derivados de 1 (beta-d-glucopiranosil)-2-tienil-metilbenceno como inhibidores de sglt
BRPI0810654A8 (pt) Tiadiazoliloxifenilamidinas, seu uso e seu método de preparação, composição e método para combate de micro-organismos indesejados, semente resistente a micro-organismo indesejado, bem como método para proteger a dita semente contra micro-organismos
BR112013026257A2 (pt) derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes
BR112013017974A2 (pt) inibidores de pirimidina girase e topoisomerase iv
WO2010047737A3 (en) Antimicrobial indoline compounds for treatment of bacterial infections
NZ600912A (en) Topical use of hydroxytyrosol and derivatives for the prevention of hiv infection
BR112018010107A2 (pt) composição farmacêutica para o tratamento ou prevenção de nash
AR071762A1 (es) Derivados 5-hidroximetil-oxazolidin-2-ona para el tratamiento de enfermedades intestinales bacteriales
WO2012017434A3 (en) Guanine nucleotide derivatives for treating bacterial infections
BR112012009311A2 (pt) composto, composição farmacêutica, e, uso do composto
BR112013024497A2 (pt) novo derivado de oxazolidinona e composição farmacêutica incluindo o mesmo
WO2009116044A3 (en) Guanine nucleotide derivatives for treating bacterial infections
MX2013007937A (es) Nuevo derivado de indol o indazol o sal del mismo.
BRPI0712312A2 (pt) Composto, processo para a produção do mesmo, composição farmacêutica, agente antimicrobiano, agente anti-mrsa, método para a prevenção ou o tratamento de uma doença infecciosa, e, uso do composto
BR112013012665A2 (pt) composto de fórmula (i), ou um sal, pró-droga ou solvato do mesmo e composição farmacêutica

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL